Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.
The Association for Research in Vision and Ophthalmology (ARVO) Foundation announced that Glenn Yiu, MD, PhD, has won the 2024 Carl Camras Translational Research Award.
This $12,000 award is granted annually to young investigators working in areas of translational research. The intent of this award is to recognize early-career researchers who show excellence in research, and their fundamental scientific discoveries, concepts and novel technologies have led to or have the promise of leading to clinical application.1
Supported by the ARVO Foundation, this award honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist.1
According to the press release1, the 2024 recipient, Yiu is recognized for his work not only as a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis, but also for his innovation.
He leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases, focusing ocular imaging technologies, gene editing and delivery, and animal models of retinal disease. Yiu reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, discovered the use of microneedles for suprachoroidal gene delivery, and pioneered important studies on drusen evolution and other retinal disease models in rhesus monkeys. Yiu also serves as director of tele-ophthalmology at UC Davis, where he has pioneered a teleretinal screening program to expand eye screening among diabetic patients in California.1
In the press release1, Yiu shared what this award means to him, saying, "I am humbled and honored to receive the Carl Camras Translational Research Award. Dr. Camras embodied the ideals of a clinician-scientist who can leverage his knowledge and compassion as a physician to develop novel therapies as a translational researcher. His breakthrough work in prostaglandin analogues and its impact on glaucoma patients worldwide reminds me of the importance of curiosity, perseverance, and empathy in bringing about new treatments and technologies. This award will inspire me to continue making greater impact on the lives of patients with retinal diseases."